192 related articles for article (PubMed ID: 15482224)
1. Chronic Pseudomonas aeruginosa infection in cystic fibrosis airway disease: metabolic changes that unravel novel drug targets.
Yoon SS; Hassett DJ
Expert Rev Anti Infect Ther; 2004 Aug; 2(4):611-23. PubMed ID: 15482224
[TBL] [Abstract][Full Text] [Related]
2. Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets.
Hassett DJ; Cuppoletti J; Trapnell B; Lymar SV; Rowe JJ; Yoon SS; Hilliard GM; Parvatiyar K; Kamani MC; Wozniak DJ; Hwang SH; McDermott TR; Ochsner UA
Adv Drug Deliv Rev; 2002 Dec; 54(11):1425-43. PubMed ID: 12458153
[TBL] [Abstract][Full Text] [Related]
3. Airway biofilms: implications for pathogenesis and therapy of respiratory tract infections.
Kobayashi H
Treat Respir Med; 2005; 4(4):241-53. PubMed ID: 16086598
[TBL] [Abstract][Full Text] [Related]
4. Pseudomonas aeruginosa hypoxic or anaerobic biofilm infections within cystic fibrosis airways.
Hassett DJ; Sutton MD; Schurr MJ; Herr AB; Caldwell CC; Matu JO
Trends Microbiol; 2009 Mar; 17(3):130-8. PubMed ID: 19231190
[TBL] [Abstract][Full Text] [Related]
5. Great phenotypic and genetic variation among successive chronic Pseudomonas aeruginosa from a cystic fibrosis patient.
Lozano C; Azcona-Gutiérrez JM; Van Bambeke F; Sáenz Y
PLoS One; 2018; 13(9):e0204167. PubMed ID: 30212579
[TBL] [Abstract][Full Text] [Related]
6. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients.
Murray TS; Egan M; Kazmierczak BI
Curr Opin Pediatr; 2007 Feb; 19(1):83-8. PubMed ID: 17224667
[TBL] [Abstract][Full Text] [Related]
7. Anaerobic Pseudomonas aeruginosa and other obligately anaerobic bacterial biofilms growing in the thick airway mucus of chronically infected cystic fibrosis patients: an emerging paradigm or "Old Hat"?
Su S; Hassett DJ
Expert Opin Ther Targets; 2012 Sep; 16(9):859-73. PubMed ID: 22793158
[TBL] [Abstract][Full Text] [Related]
8. Lung infection with alginate-producing, mucoid Pseudomonas aeruginosa in cystic fibrosis.
Pedersen SS
APMIS Suppl; 1992; 28():1-79. PubMed ID: 1449848
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Rhesus Theta-Defensin-1 in Experimental Models of Pseudomonas aeruginosa Lung Infection and Inflammation.
Bensman TJ; Jayne JG; Sun M; Kimura E; Meinert J; Wang JC; Schaal JB; Tran D; Rao AP; Akbari O; Selsted ME; Beringer PM
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559270
[TBL] [Abstract][Full Text] [Related]
10. Persistent infections and immunity in cystic fibrosis.
Yu H; Head NE
Front Biosci; 2002 Feb; 7():d442-57. PubMed ID: 11815305
[TBL] [Abstract][Full Text] [Related]
11. A physical linkage between cystic fibrosis airway surface dehydration and Pseudomonas aeruginosa biofilms.
Matsui H; Wagner VE; Hill DB; Schwab UE; Rogers TD; Button B; Taylor RM; Superfine R; Rubinstein M; Iglewski BH; Boucher RC
Proc Natl Acad Sci U S A; 2006 Nov; 103(48):18131-6. PubMed ID: 17116883
[TBL] [Abstract][Full Text] [Related]
12. Harnessing Neutrophil Survival Mechanisms during Chronic Infection by
Marteyn BS; Burgel PR; Meijer L; Witko-Sarsat V
Front Cell Infect Microbiol; 2017; 7():243. PubMed ID: 28713772
[TBL] [Abstract][Full Text] [Related]
13. Understanding bacterial biofilms in patients with cystic fibrosis: current and innovative approaches to potential therapies.
Høiby N
J Cyst Fibros; 2002 Dec; 1(4):249-54. PubMed ID: 15463822
[TBL] [Abstract][Full Text] [Related]
14. Microevolution of Pseudomonas aeruginosa to a chronic pathogen of the cystic fibrosis lung.
Hogardt M; Heesemann J
Curr Top Microbiol Immunol; 2013; 358():91-118. PubMed ID: 22311171
[TBL] [Abstract][Full Text] [Related]
15. Pseudomonas aeruginosa and the airways disease of cystic fibrosis.
Hata JS; Fick RB
Clin Chest Med; 1988 Dec; 9(4):679-89. PubMed ID: 3148384
[TBL] [Abstract][Full Text] [Related]
16. The mucoid switch in Pseudomonas aeruginosa represses quorum sensing systems and leads to complex changes to stationary phase virulence factor regulation.
Ryall B; Carrara M; Zlosnik JE; Behrends V; Lee X; Wong Z; Lougheed KE; Williams HD
PLoS One; 2014; 9(5):e96166. PubMed ID: 24852379
[TBL] [Abstract][Full Text] [Related]
17. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients.
Worlitzsch D; Tarran R; Ulrich M; Schwab U; Cekici A; Meyer KC; Birrer P; Bellon G; Berger J; Weiss T; Botzenhart K; Yankaskas JR; Randell S; Boucher RC; Döring G
J Clin Invest; 2002 Feb; 109(3):317-25. PubMed ID: 11827991
[TBL] [Abstract][Full Text] [Related]
18. Pseudomonas aeruginosa biofilms in cystic fibrosis.
Høiby N; Ciofu O; Bjarnsholt T
Future Microbiol; 2010 Nov; 5(11):1663-74. PubMed ID: 21133688
[TBL] [Abstract][Full Text] [Related]
19. Mucoid Pseudomonas aeruginosa isolates maintain the biofilm formation capacity and the gene expression profiles during the chronic lung infection of CF patients.
Lee B; Schjerling CK; Kirkby N; Hoffmann N; Borup R; Molin S; Høiby N; Ciofu O
APMIS; 2011 Apr; 119(4-5):263-74. PubMed ID: 21492226
[TBL] [Abstract][Full Text] [Related]
20. Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.
Assael BM
Expert Rev Anti Infect Ther; 2011 Nov; 9(11):967-73. PubMed ID: 22029514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
